Boerhaavia diffusa stimulates cell-mediated immune response by upregulating IL-2 and downregulating the pro-inflammatory cytokines and GM-CSF in B16F-10 metastatic melanoma bearing mice

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 1, 2008, Pages 17-29

  Manu, K A ^a   Kuttan, Girija ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BOERHAAVIA DIFFUSA EXTRACT; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; C57BL MOUSE; CELLULAR IMMUNITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MELANOMA; MELANOMA B16; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NYCTAGINACEAE; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 42049101865     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591-602, 2005.
2. Poste G. Pathogenesis of metastatic disease; Implications for current therapy and for the development of new therapeutic strategies . Cancer Treat Rep 70: 1223-1227, 1986.
3. Albino AP, Reed JA, Mc Nutt NS. Molecular biology of cutaneous malignant melanoma. In: De Vita VT Jr, Hellman S and Rosenberg SA, eds. Cancer. Principles and practice of oncology, Vol. 1. Lippincott-Raven, New York, pp 1935-1937, 1997.
4. Liu Y, Ng K, Lillehei KO. Cell mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer control 10: 138-146, 2003.
5. Ramirez-Montagut T, Turk MJ, Wolchole JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22: 3180-3187, 2003.
6. Lala PK, Santer V, Libenson H, Parhar RS. Changes in host natural killer cell population in mice during tumor development. 1. Kinetics and in vivo significance. Cell Immunol 93: 250-264, 1985.
7. 2- mediator inactivation of various killer lineage cell, by tumor bearing host macrophages. J.Leukocyte boil 44: 474-484, 1988.
8. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature :335-338, 1981.
9. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cytotoxocity. Proc. Natl Acad Sci. USA 96:5640-5644, 1999.
10. Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P. Antitumor effects of recombinant human interleukin-1 alpha on RIF-1 and Panc02 solid tumors. Cancer Res 48: 6011-6016, 1988.
11. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 355: 248-250, 2000.
12. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193:1007-1008, 1976.
13. Ralph P, Sampson-Johannes A. Macrophage growth and stimulating factor, M-CSF. Prog Clin Biol Res 338: 43-6, 1990.
14. Sherr CJ. Regulation of mononuclear phagocyte proliferation by colony-stimulating factor-1. Int J Cell Cloning 8:46-60, 1990.
15. Kuttan G, Kuttan R. Immunomodulatory activity of Viscum album extract Immunol Invest 21: 285-296, 1992.
16. Singh VK, Aggarwal SS, Gupta BM. Immunomodulatory activity of Panax ginseng extract. Plant. Med. 50: 462-465, 1984.
17. Mathew S, Kuttan G. Immunomodulatory and antitumor activities of Tinospora cordifolia. Fitoterapia, 70, 35-43, 1999.
18. Sunila ES, Kuttan G. Immunomodulatory and antitumor activity of Piper longum Linn. And Piperine. Ethnopharmacol 90: 339-346, 2004.
19. Hajto T, Hostanska K, Gabius HJ., J. Modulatory potential of the beta-galactoside-specific lectin from mistletoe extract (IScador) on the host defense system in vivo in rabbits and patients. Cancer Res 49: 4803-4808, 1989.
20. CSIR. The Wealth of India: Raw Materials Vol. 7 B. CSIR, New Delhi, India, p174, 1988.
21. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Ray, C. Screening of Indian plants for biological activity: Part I. Indian Journal of Experimental Biology 6:232-247, 1968.
22. Bhalla TN, Gupta MB, Sheth PK, Bhargava KP. Antiinflammatory activity of Boerhaavia diffusa. Indian Journal of Physiology and Pharmacology 12:37, 1968.
23. Jain, G.K. and Khanna, N.M. Punarnavoside: A new antifibrinolytic agent from Boerhaavia diffusa Linn. Indian Journal of Chemistry 28: 163-166, 1989.
24. Adesina SK. Anticonvulsant properties of the roots of Boerhaavia diffusa. Quarterly Journal of Crude Drug Research 17:84-86, 1979.
25. Olukoya DK, Idika N, Odugbemi T. Antibacterial activity of some medicinal plants from Nigeria. Journal of Ethnopharmacology 39:69-72, 1993.
26. Kim YB, Huh ND, Koren HS, Amos DB. Natural Killing (NK) and antibody dependent cellular cytotoxicity(ADCC) in specific pathogen free (SPF) miniature swine and germ free piglets. 1. comparison of NK and ADCC. J. Immunol 125: 755-762, 1980.
27. Gupta SK, Bhattacharya B. Cytotoxicity assays. In: Talwar GP, Ed. A handbook of Practical Immunology. Vikas Publishing house, New Delhi, pp328-333, 1983.
28. Puente N, Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenas cin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 167: 6431-40, 2001.
29. Rosenberg SA. Identification of cancer antigens: impact on development of cancer immunotherapies . Cancer J 6: 200-207, 2000.
30. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trend Immunol. 22:633-640, 2001.
31. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA 92: 377-381. 1995.
32. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russel SM, Drago J, Noguchi M, Grinberg A Bloom ET. Defective lymphoid development in mice lacking the expression of the common cytokine receptor gamma chain. Immunity 2: 223-38, 1995.
33. Trinchieri G. Biology of natural killer cells. Adv. Immunol 47:187-376, 1989.
34. Whiteside TL, Herberman RB. Human natural killer cells in health and disease. Clinincal and diagnostic laboratory Immunology 1: 125-33, 1994.
35. Aboud M, Kingsmore S, Segal S. Role of natural killer cells in controlling local tumor formation and metastatic manifestation of different 3LL Lewis lung carcinoma cell clones. Nat Immun 1993;12:17-24
36. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97:2731-2736, 2000.
37. Kuttan G, Kuttan R. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract cellular proliferation. Cancer letters 66: 123-130, 1992.
38. Misawa E, Sakurai T, Yamada M, Hayasawa H, Motoyoshi K. Effects of macrophage colony stimulating factor and interleukin-2 administration on NK1.1+cells in mice. Int J Pharmacology 22: 967-971, 2000.
39. Cailiguiri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J.Clin.Invest. 91: 123-132, 1993.
40. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 10: 258-266, 1996.
41. Goldbsy RA, Kindt TJ, Osborne BA, Kuby J. Immunology. WH Freeman, New York, pp 178-89, 2002.
42. Szebeni J, Muggia FM, Alving CR. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel : an in vitro study. J Natl Cancer Inst 90; 300-306, 1998.
43. Huang S, De Guzman A, Bucana CD, Fidler IJ. Level of Interleukin-8 expression by metastatic human melanoma cells directly correlates consticutive NF-kB activity. Cytokines, Cellular and Molecular Therapy 6: 9-17, 2000.
44. Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine. 8: 578-85, 1996.
45. Naylor MS, Stamp GW, Faulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invent 91: 2194-206, 1993.
46. Kaoru T, Tohru M, Haruhiro T, Hiroshi A, Naomi S, Shinichi T, Takeshige. Critical Roles of Muscle-Secreted Angiogenic Factors in Therapeutic Neovascularization. Circulation Research 98:194-1210, 2006.
47. Vidal-Vanaclocha F, Fantuzzi G, endoza L, uentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novik D, Rubinstein M, Dinarello CA. 11-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. USA. 97:734-39, 2000.
48. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY. Interleukin-6 in cervical cancer : the relationship with vascular endothelial growth factor. Gynecologic Oncology 82: 49-56,2001.
49. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517-1527, 2003.
50. Takeda K, Hatakeyama K, Tsuchiya Y, Rikiishi H, Kumagai K. A correlation between GM-CSF gene expression and metastases in murine tumors. International Journal of Cancer 47: 413-420. 1991.
51. Bussolino F, Wang JM, Defillipi P, Turrini F, Sanavio F, Edgell CJ, Aglietta M, Arese P, Mantovani A. Granulocyte- and granulocyte- macrophage- colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 337: 471-473, 1989.